NCT00955630View on ClinicalTrials.gov

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2010

Conditions

Ocular Histoplasmosis Syndrome

Interventions

DRUG

ranibizumab

3 monthly injections of ranibizumab followed by prn injections for the remainder of the study

DRUG

ranibizumab

prn injections of ranibizumab throughout the study

Trial Locations (1)

40509

RECRUITING

Retina Associates of Kentucky, Lexington

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Retina Associates of Kentucky

OTHER